samedan logo
 
 
 
spacer
home > ebr > summer 2004 > functional genomics in trypanosomes: using rna interference to assign gene function and validate drug targets in tropical disease agents
PUBLICATIONS
European Biopharmaceutical Review

Functional Genomics in Trypanosomes: Using RNA Interference to Assign Gene Function and Validate Drug Targets in Tropical Disease Agents

The World Health Organization has designated many tropical protozoan pathogens as high priority re-emergent disease agents. Asymmetric funding - many of these pathogens affect citizens of countries with low or no economic wealth - has meant that the development of new therapeutics is slow or non-existent. For researchers interested in Trypanosoma brucei, the causative agent of human African sleeping sickness, a combination of renewed interest, completion of the genome project and RNA interference technology may herald a new period of advance in both therapeutic development and understanding of basic biology. Can the research community deliver?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Mark C Field, Department of Biological Sciences at Imperial College, London, and Dr Mark Carrington, Department of Biochemistry at the University of Cambridge, UK

Dr Mark C Field is at the Department of Biological Sciences, Imperial College. He was educated at Oxford Univeristy and completed his doctoral work there at the Glycobiology Institute on glyoprotein structure and function. His postdoctoral career began in the US where he started to work on trypanosomatids at the Rockefeller and Stanford Universities, as well as a short period at Genentech Inc. In 1994, he established his own research group at Imperial College, London, which focuses on the molecular cell biology of Trypanosoma brucei.


Dr Mark Carrington is at the Department of Biochemistry, University of Cambridge. He was educated at Cambridge, obtaining his PhD in Plant Molecular Biology. He has worked on trypanosomes since the start of his postdoctoral career and has extensive experience in the study of protein structure and RNA processing, and is interested in the development of therapeutics based on surface proteins and on host-resistance mechanisms.

spacer
Dr Mark C Field
spacer
spacer
spacer
Dr Mark Carrington
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement